Jiangxi Antai R & D center, with initial investment of 15 million yuan, officially opened in 2013. The center has more than 20 professional and technical personnel, including 3 doctoral, 8 master's degree, all bachelor's degree or above. They mainly undertake the company's new drug research and development, pilot scale test, technology study, technology transfer and so on. The center has Agilent HPLC, Agilent GC, AAS, SHIMADZU infrared spectrophotometer, automatic dissolution tester and other analytical testing equipment. It’s divided into departments of Preparation, Analysis, Synthesis, Test department, Registration and project reporting department. The center has invested 5% of the group's sales revenue each year.
Butoconazole nitrate is imidazole antifungal drug for the topical treatment for vulvovaginal candidiasis (VVC) that caused by Candida. 2% of butoconazole nitrate vaginal cream are recommended by the U. S. centers for Disease Control and Prevention (CDC) center as the preferred drug for the treatment of vulvovaginal candidiasis. In the United States, the incidence of VVC was the highest (39%) in all patients with genital inflammation. The incidence rate of VVC was the highest (11.6%) in the Chinese Department of gynaecology clinic (31.3%). It is estimated that 75% of women of childbearing age have had at least 1 VVC, 40% to 50% of patients have a recurrence of experience. After many years of clinical application, the effect of Butoconazole nitrate was proved to have definite curative effect, good safety and low incidence of adverse reactions. Successfully development of the drug will provide a new choice for VVC clinical treatment, provide more safe, effective, convenient and comfortable drug use for patients, which has great social benefits; at the same time, due to the obvious advantages of the product, after the listing it will gradually become mainstream products in the treatment of VVC drug, which will have huge economic benefits.
As the first drug to treat premature ejaculation, it is a new type of 5- serotonin reuptake inhibitors (SSRI) drug. In December 2008, dapoxetine has been accredited by seven European countries, and used as a new drug in the treatment of premature ejaculation and approved for use by the European countries, Finland and Sweden, 18 to 64 years of age, male as applicable to the crowd. The listing of dapoxetine in European market has greatly encouraged scientific research workers, and the market size of it will up to $20-50 billion.
Enteric coated capsules is to prevent drug on gastric mucosal stimulation, to prevent nausea caused by the release of drug in stomach, and increase the drug stability, increase the role of local treatment, increasing drug concentration and improve the biological utilization, etc.. At present, enteric empty capsule industry in our country has an annual growth speed in more than 20%, but the industrialization level and technology content of enteric empty capsule still need to be improved. About this project, we’ll research from the enteric coating material, prescription and technology, equipment design, production environment for all-round development, in the hope of reaching the level of the domestic first-class.